Quantum Biopharma amended its prior regulatory report in connection with registration number 333-276264, while leaving the remaining content unchanged except where later documents supersede it. Investors receive a narrowly scoped update, with the earlier report continuing as part of the record from its original furnishing date.

Key Highlights

  • Quantum Biopharma identifies itself as a foreign private issuer.
  • The company selected the annual-report framework available under Form 20-F.
  • Quantum Biopharma signed the report under the Securities Exchange Act of 1934.

Quantum Biopharma Ltd. (NASDAQ: QNTM) amended an earlier regulatory report linked to 333-276264, limiting the update to the changes identified in Amendment No. 1. The company says all other portions of the earlier report remain unchanged. The prior report continues as part of the record from the date it was initially furnished, except where later documents or reports supersede it.

Amendment Leaves Earlier Report in Place

The amendment is identified as a foreign private issuer report from Quantum Biopharma. The company’s principal executive offices are in Toronto, Ontario. Quantum Biopharma indicates that it files or will file annual reports under Form 20-F rather than Form 40-F. The report is signed on the company’s behalf by an authorised representative under the Securities Exchange Act of 1934.

Scope of the Report Update

The stated scope is limited to the amendment to the earlier report. Quantum Biopharma says there are no other changes to that report. The earlier report remains incorporated into the record from its initial furnishing date, subject to documents or reports filed or furnished later that supersede it. The company’s signature confirms the report was executed on its behalf.